I call it 'mesearch', as I tasked myself to become an expert in MY ADHD (as we all should, really
Patients with conditions such as depression or eating disorders may need additional considerations before starting GLP-1 therapy
Understanding where things are heading provides additional context for the Toujeo versus GLP-1 discussion
Patients treated with tesamorelin for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
Certificate of Analysis (COA): Available here
Shah notes that it can also happen with tirzepatides like Zepbound and Mounjaro, among other medications in the class of drugs known as GLP-1 receptor agonists